RA Capital Management
RA Capital Management, L.P. is a Boston-based venture capital firm that specializes in early and multi-stage investments in the healthcare and life sciences sectors. Founded in 2001, the firm focuses on companies developing drugs, medical devices, diagnostics, and biotechnology. RA Capital invests in a range of funding stages, from seed funding to later rounds, and is known for its willingness to invest under $1 million in initial rounds or larger sums in established companies. The firm's investment strategy emphasizes companies with promising technologies and products, particularly in areas like prevention, cost-effective diagnostics, genetic testing, and personalized medicine. The team consists of professionals with backgrounds in biology, chemistry, and medicine, enabling them to provide valuable insights into data, regulatory processes, and market demands. Additionally, RA Capital often seeks to co-invest and take board positions in its portfolio companies, enhancing their strategic growth opportunities.
Developer of clinical-stage neuroscience therapeutics intended to harness novel neuroplasticity-promoting treatments for difficult-to-treat neuropsychiatric and neurological disorders. The company's compounds include non-hallucinogenic, non-psychotomimetic, and non-dissociative versions of psychedelic components, enabling healthcare service providers to address significant mental health challenges through phenotypic drug discovery across various chemotypes and mechanisms of action.
Developer of clinical-stage neuroscience therapeutics intended to harness novel neuroplasticity-promoting treatments for difficult-to-treat neuropsychiatric and neurological disorders. The company's compounds include non-hallucinogenic, non-psychotomimetic, and non-dissociative versions of psychedelic components, enabling healthcare service providers to address significant mental health challenges through phenotypic drug discovery across various chemotypes and mechanisms of action.
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.
Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.
Cybin is a biopharmaceutical company dedicated to developing safe and effective therapeutics using psychedelic and medicinal mushrooms. The company focuses on creating psilocybin-based products in regions where such substances are permitted, while also conducting clinical studies across North America and other areas through collaborations with academic and institutional partners. Cybin's efforts encompass the advancement of psychedelic-based therapies, innovative delivery mechanisms, and the development of novel compounds aimed at addressing a range of mental health issues, including various psychiatric and neurological conditions.
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.
Braeburn Inc. is a pharmaceutical company focused on developing and commercializing treatments for serious central nervous system disorders, particularly opioid addiction. Founded in 2012 and based in Plymouth Meeting, Pennsylvania, Braeburn aims to address the significant challenges posed by opioid use disorder, a chronic condition that leads to structural and functional changes in the brain. The company's lead product is BRIXADI, an extended-release injectable formulation of buprenorphine designed for the treatment of moderate to severe opioid use disorder. Braeburn is dedicated to advancing next-generation therapies that offer individualized dosing regimens and various delivery options, thereby providing effective solutions for patients, healthcare providers, and society at large.
Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating chronic pain while addressing the concerns of prescription drug abuse. The company utilizes its patented DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release profiles and safety of medications despite potential misuse methods such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an extended-release oral formulation of oxycodone designed to deter abuse, as well as Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol respectively, for managing severe pain and acute pain in adults. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions for patients with chronic pain, utilizing formulation improvements backed by strong intellectual property protections.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.